+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Effect of antiflagellar human monoclonal antibody on gut-derived Pseudomonas aeruginosa sepsis in mice



Effect of antiflagellar human monoclonal antibody on gut-derived Pseudomonas aeruginosa sepsis in mice



Clinical and Diagnostic Laboratory Immunology 6(4): 537-541



We evaluated the effect of antiflagellar human monoclonal antibody on gut-derived Pseudomonas aeruginosa sepsis. Mice were given a suspension of P. aeruginosa SP10052 in their drinking water and were simultaneously treated with ampicillin (200 mg/kg of body weight) to disrupt the normal bacterial flora. Cyclophosphamide was then administered to induce leukopenia and translocation of the P. aeruginosa that had colonized the gastrointestinal tract, thereby producing gut-derived generalized sepsis. In this model, intraperitoneal injection of 100 microg of antiflagellar human monoclonal antibody (SC-1225) per mouse for 5 consecutive days significantly (P < 0.01) increased the survival rate compared with that for mice treated with bovine serum albumin (BSA). Treatment with SC-1225 significantly reduced the average number of viable bacteria in portal blood, liver, and heart blood compared with the average number after treatment with BSA. Furthermore, the presence in serum of the inflammatory cytokines tumor necrosis factor alpha and interleukin 6 were evaluated as markers of severity of infection, and the results showed that the levels of these cytokines in mice treated with SC-1225 were significantly decreased in comparison with those in BSA-treated control mice. Although there was no significant difference in the number of bacteria that colonized the intestine, SC-1225 treatment significantly increased bacterial opsonophagocytosis by cultured peritoneal macrophages from mice with or without cyclophosphamide pretreatment. Our results indicate that antiflagellar human monoclonal antibody SC-1225 protects mice against gut-derived sepsis caused by P. aeruginosa and suggest that such an effect is due to its opsonophagocytic activity and the reduced motility of the translocated bacteria once the bacteria move from the intestine into the bloodstream.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 010517182

Download citation: RISBibTeXText

PMID: 10391858


Related references

Effect of human monoclonal antibody against O-antigen and core-antigen of lipopolysaccharide on gut-derived Pseudomonas aeruginosa sepsis in mice. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 43: 66, 2003

Multi-valent human monoclonal antibody preparation against Pseudomonas aeruginosa derived from transgenic mice containing human immunoglobulin loci is protective against fatal pseudomonas sepsis caused by multiple serotypes. Vaccine 23(25): 3264-3271, 2005

Effects of a human antiflagellar monoclonal antibody in combination with antibiotics on Pseudomonas aeruginosa infection. Antimicrobial Agents and ChemoTherapy 36(6): 1290-1295, 1992

Human monoclonal antibodies against Pseudomonas aeruginosa lipopolysaccharide derived from transgenic mice containing megabase human immunoglobulin loci are opsonic and protective against fatal pseudomonas sepsis. Infection and Immunity 69(4): 2223-2229, 2001

Protection against pseudomonas aeruginosa pa sepsis in burned mice with cross reactive monoclonal antibody mca. Abstracts of the Annual Meeting of the American Society for Microbiology 88: 49, 1988

Human monoclonal antibody against Pseudomonas aeruginosa LPS derived from transgenic XenoMouseTM mice is opsonic and highly protective in the neutropenic mouse model of sepis. Clinical Infectious Diseases 31(1): 213, 2000

Inhibition of bacterial motility with human antiflagellar monoclonal antibodies attenuates Pseudomonas aeruginosa-induced pneumonia in the immunocompetent rat. Infection and Immunity 62(11): 4825-4830, 1994

Immunoprophylaxis of pseudomonas aeruginosa burn wound sepsis with a cross reactive human monoclonal antibody. Abstracts of the Annual Meeting of the American Society for Microbiology 88: 126, 1988

Effect of immunisation with Pseudomonas aeruginosa on gut-derived sepsis in mice. Journal of Medical Microbiology 47(4): 295-301, 1998

Effect of Interleukin-10 on Gut-Derived Sepsis Caused by Pseudomonas aeruginosa in Mice. Antimicrobial Agents and Chemotherapy 42(11): 2853-2857, 1998

Effect of interleukin-10 on gut-derived sepsis caused by Pseudomonas aeruginosa in mice. Antimicrobial Agents and ChemoTherapy 42(11): 2853-2857, 1998

Immunomodulating effect of fosfomycin on gut-derived sepsis caused by Pseudomonas aeruginosa in mice. Antimicrobial Agents and ChemoTherapy 41(2): 308-313, 1997

Protection studies in a mouse burn wound sepsis model with a human anti pseudomonas aeruginosa flagella monoclonal antibody and its fab 2 and fab fragments. Abstracts of the Annual Meeting of the American Society for Microbiology 90: 123, 1990

Comparison of pre- versus post-sepsis treatment with polyclonal immunoglobulin versus O serotype specific monoclonal antibody in burned Pseudomonas aeruginosa infected mice. Serodiagnosis and ImmunoTherapy in Infectious Disease 4(3): 221-230, 1990

Combination therapy of Pseudomonas aeruginosa pyelonephritis in neutropenic mice with human antilipopolysaccharide monoclonal antibody and cefsulodin. Journal Of Urology. 155(6): 2094-2097, 1996